Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry

Christian Ukena; Felix Mahfoud; Sebastian Ewen; Andreas Bollmann; Gerhard Hindricks; Boris A Hoffmann; Dominik Linz; Dan Musat; Valerie Pavlicek; Eberhard Scholz; Dierk Thomas; Stephan Willems; Michael Böhm; Jonathan S Steinberg

doi:10.1007/s00392-016-1012-y

Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry

Standard

Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. / Ukena, Christian; Mahfoud, Felix; Ewen, Sebastian; Bollmann, Andreas; Hindricks, Gerhard; Hoffmann, Boris A; Linz, Dominik; Musat, Dan; Pavlicek, Valerie; Scholz, Eberhard; Thomas, Dierk; Willems, Stephan; Böhm, Michael; Steinberg, Jonathan S.

in: CLIN RES CARDIOL, Jahrgang 105, Nr. 10, 10.2016, S. 873-879.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ukena, C, Mahfoud, F, Ewen, S, Bollmann, A, Hindricks, G, Hoffmann, BA, Linz, D, Musat, D, Pavlicek, V, Scholz, E, Thomas, D, Willems, S, Böhm, M & Steinberg, JS 2016, 'Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry', CLIN RES CARDIOL, Jg. 105, Nr. 10, S. 873-879. https://doi.org/10.1007/s00392-016-1012-y

APA

Ukena, C., Mahfoud, F., Ewen, S., Bollmann, A., Hindricks, G., Hoffmann, B. A., Linz, D., Musat, D., Pavlicek, V., Scholz, E., Thomas, D., Willems, S., Böhm, M., & Steinberg, J. S. (2016). Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. CLIN RES CARDIOL, 105(10), 873-879. https://doi.org/10.1007/s00392-016-1012-y

Vancouver

Ukena C, Mahfoud F, Ewen S, Bollmann A, Hindricks G, Hoffmann BA et al. Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. CLIN RES CARDIOL. 2016 Okt;105(10):873-879. https://doi.org/10.1007/s00392-016-1012-y

Bibtex

@article{67b727f880a94a51a34c3cfd0b14f9b4,

title = "Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry",

abstract = "INTRODUCTION: Ventricular arrhythmias (VAs) in patients with chronic heart failure (CHF) are sometimes refractory to antiarrhythmic drugs and cardiac ablation. This study aimed to investigate catheter-based renal sympathetic denervation (RDN) as antiarrhythmic strategy in refractory VA.METHODS: These are the first data from a pooled analysis of 13 cases from five large international centers (age 59.2 ± 14.4 years, all male) with CHF (ejection fraction 25.8 ± 10.1 %, NYHA class 2.6 ± 1) presented with refractory VA who underwent RDN. Ventricular arrhythmias, ICD therapies, clinical status, and blood pressure (BP) were evaluated before and 1-12 months after RDN.RESULTS: Within 4 weeks prior RDN, a median of 21 (interquartile range 10-30) ventricular tachycardia (VT) or fibrillation (VF) episodes occurred despite antiarrhythmic drugs and prior cardiac ablation. RDN was performed bilaterally with a total number of 12.5 ± 3.5 ablations and without peri-procedural complications. One and 3 months after RDN, VT/VF episodes were reduced to 2 (0-7) (p = 0.004) and 0 (p = 0.006), respectively. Four (31 %) and 11 (85 %) patients of these 13 patients were free from VA at 1 and 3 months. Although BP was low at baseline (116 ± 18/73 ± 13 mmHg), no significant changes of BP or NYHA class were observed after RDN. During follow-up, three patients died from non-rhythm-related causes.CONCLUSIONS: In patients with CHF and refractory VA, RDN appears to be safe concerning peri-procedural complications and blood pressure changes, and is associated with a reduced arrhythmic burden.",

keywords = "Aged, Anti-Arrhythmia Agents/therapeutic use, Blood Pressure, Disease-Free Survival, Heart Failure/complications, Heart Rate/drug effects, Humans, Kidney/innervation, Male, Middle Aged, Postoperative Complications/etiology, Registries, Sympathectomy/adverse effects, Sympathetic Nervous System/physiopathology, Tachycardia, Ventricular/diagnosis, Time Factors, Treatment Outcome, Ventricular Fibrillation/diagnosis",

author = "Christian Ukena and Felix Mahfoud and Sebastian Ewen and Andreas Bollmann and Gerhard Hindricks and Hoffmann, {Boris A} and Dominik Linz and Dan Musat and Valerie Pavlicek and Eberhard Scholz and Dierk Thomas and Stephan Willems and Michael B{\"o}hm and Steinberg, {Jonathan S}",

year = "2016",

month = oct,

doi = "10.1007/s00392-016-1012-y",

language = "English",

volume = "105",

pages = "873--879",

journal = "CLIN RES CARDIOL",

issn = "1861-0684",

publisher = "D. Steinkopff-Verlag",

number = "10",

}

RIS

TY - JOUR

T1 - Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry

AU - Ukena, Christian

AU - Mahfoud, Felix

AU - Ewen, Sebastian

AU - Bollmann, Andreas

AU - Hindricks, Gerhard

AU - Hoffmann, Boris A

AU - Linz, Dominik

AU - Musat, Dan

AU - Pavlicek, Valerie

AU - Scholz, Eberhard

AU - Thomas, Dierk

AU - Willems, Stephan

AU - Böhm, Michael

AU - Steinberg, Jonathan S

PY - 2016/10

Y1 - 2016/10

N2 - INTRODUCTION: Ventricular arrhythmias (VAs) in patients with chronic heart failure (CHF) are sometimes refractory to antiarrhythmic drugs and cardiac ablation. This study aimed to investigate catheter-based renal sympathetic denervation (RDN) as antiarrhythmic strategy in refractory VA.METHODS: These are the first data from a pooled analysis of 13 cases from five large international centers (age 59.2 ± 14.4 years, all male) with CHF (ejection fraction 25.8 ± 10.1 %, NYHA class 2.6 ± 1) presented with refractory VA who underwent RDN. Ventricular arrhythmias, ICD therapies, clinical status, and blood pressure (BP) were evaluated before and 1-12 months after RDN.RESULTS: Within 4 weeks prior RDN, a median of 21 (interquartile range 10-30) ventricular tachycardia (VT) or fibrillation (VF) episodes occurred despite antiarrhythmic drugs and prior cardiac ablation. RDN was performed bilaterally with a total number of 12.5 ± 3.5 ablations and without peri-procedural complications. One and 3 months after RDN, VT/VF episodes were reduced to 2 (0-7) (p = 0.004) and 0 (p = 0.006), respectively. Four (31 %) and 11 (85 %) patients of these 13 patients were free from VA at 1 and 3 months. Although BP was low at baseline (116 ± 18/73 ± 13 mmHg), no significant changes of BP or NYHA class were observed after RDN. During follow-up, three patients died from non-rhythm-related causes.CONCLUSIONS: In patients with CHF and refractory VA, RDN appears to be safe concerning peri-procedural complications and blood pressure changes, and is associated with a reduced arrhythmic burden.

AB - INTRODUCTION: Ventricular arrhythmias (VAs) in patients with chronic heart failure (CHF) are sometimes refractory to antiarrhythmic drugs and cardiac ablation. This study aimed to investigate catheter-based renal sympathetic denervation (RDN) as antiarrhythmic strategy in refractory VA.METHODS: These are the first data from a pooled analysis of 13 cases from five large international centers (age 59.2 ± 14.4 years, all male) with CHF (ejection fraction 25.8 ± 10.1 %, NYHA class 2.6 ± 1) presented with refractory VA who underwent RDN. Ventricular arrhythmias, ICD therapies, clinical status, and blood pressure (BP) were evaluated before and 1-12 months after RDN.RESULTS: Within 4 weeks prior RDN, a median of 21 (interquartile range 10-30) ventricular tachycardia (VT) or fibrillation (VF) episodes occurred despite antiarrhythmic drugs and prior cardiac ablation. RDN was performed bilaterally with a total number of 12.5 ± 3.5 ablations and without peri-procedural complications. One and 3 months after RDN, VT/VF episodes were reduced to 2 (0-7) (p = 0.004) and 0 (p = 0.006), respectively. Four (31 %) and 11 (85 %) patients of these 13 patients were free from VA at 1 and 3 months. Although BP was low at baseline (116 ± 18/73 ± 13 mmHg), no significant changes of BP or NYHA class were observed after RDN. During follow-up, three patients died from non-rhythm-related causes.CONCLUSIONS: In patients with CHF and refractory VA, RDN appears to be safe concerning peri-procedural complications and blood pressure changes, and is associated with a reduced arrhythmic burden.

KW - Aged

KW - Anti-Arrhythmia Agents/therapeutic use

KW - Blood Pressure

KW - Disease-Free Survival

KW - Heart Failure/complications

KW - Heart Rate/drug effects

KW - Humans

KW - Kidney/innervation

KW - Male

KW - Middle Aged

KW - Postoperative Complications/etiology

KW - Registries

KW - Sympathectomy/adverse effects

KW - Sympathetic Nervous System/physiopathology

KW - Tachycardia, Ventricular/diagnosis

KW - Time Factors

KW - Treatment Outcome

KW - Ventricular Fibrillation/diagnosis

U2 - 10.1007/s00392-016-1012-y

DO - 10.1007/s00392-016-1012-y

M3 - SCORING: Journal article

C2 - 27364940

VL - 105

SP - 873

EP - 879

JO - CLIN RES CARDIOL

JF - CLIN RES CARDIOL

SN - 1861-0684

IS - 10

ER -